Stago Establishes Stake In Thrombin Generation Through Acquisition Of Thrombinoscope BV

Source : Diagnostica Stago, Inc.

April 1, 2010, Parsippany, NJ, USA – Diagnostica Stago, Inc. (DSI), recently finalized the acquisition of Thrombinoscope BV, based in Maastricht, The Netherlands. This company, originally developed at Maastricht University, researches, develops and markets thrombin generation (TG) systems through the use of the Calibrated Automated Thrombogram ® (CAT) system. This system is available for research-only use – and should not be used for diagnostic purposes.

“The development potential of this new TG approach in hemostasis using the CAT system is very promising,” noted Stephane Zamia, PhD and CEO of DSI. “The addition of this approach to Stago’s portfolio will allow our customers to measure TG in real-time and in larger, scalable studies.” What is Thrombin generation (TG)? TG is a universal test capable of assessing a patient’s global hemostatic balance in the case of hemorrhage or thrombosis. Few methods previously existed that allowed for TG standardization and calibration.

Thrombinoscope introduced a patented, sample-specific calibrator that allows for error correction due to inter-subject plasma composition and color variations, as well as substrate consumption. This method is both specific and sensitive, thus giving increased relevance to this hemostatic test in academic research centers, pharmaceutical companies and contract research organizations.

About Diagnostica Stago, Inc.

Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information about any Stago product or service, please call 800-222-COAG or visit our website at www.stago-us.com.

###

  • <<
  • >>

Articles List

  • More than One Way to Change a Base

    More than One Way to Change a Base

    It’s easier than ever these days to clone and sequence DNA. Thanks to CRISPR/Cas and related technologies, it’s even straightforward to rewrite genomic sequences in living cells and organisms. But as powerful as it is, CRISPR, et al., cannot induce genetic rewrites in a test tube—genome editing requires cellular machinery to repair the DNA breaks the methods produce. Instead, researchers interested in mutating cloned genes on plasmids must revert to a tried-and-true method, site-directed mutagenesis. First described in the 1970s—and earning its inventor a share of the Nobel Prize in Chemistry in 1993—site-directed mutagenesis uses short oligonucleotides to introduce single base changes, as well as insertions and deletions, to DNA plasmids. Researchers can use the method to swap amino acids in expressed proteins, test clinically relevant mutations and tweak promoters. But there’s more than one way to change a base, and molecular-tools vendors have commercialized multiple strategies. Here, we review some of the more popular approaches to site-directed mutagenesis.
  • What Doesn’t Kill You … Testing for Chemical Toxicity

    What Doesn’t Kill You … Testing for Chemical Toxicity

    Understanding the effects of small molecules, compounds and chemicals on cells is the very core of drug discovery, one in which the pharmaceutical industry continues to invest billions of dollars. Yet alongside the question of whether such entities have a desired effect looms that of whether they have a toxic effect on those cells—and ultimately the tissues and organisms the cells compose. This question has equal importance to those who protect our environment and assure that our food is safe to eat. Testing chemical toxicity can take many forms, from looking for simple surrogates of death, such as the inability to exclude trypan blue, to sophisticated measures of changes in a specific cell type’s physiology. Various assays look at pathways leading to cell death, membrane integrity, depletion of energy, ability to proliferate and changes in differentiation. They are accomplished using instruments ranging from a hemocytometer and light microscope; to a Coulter counter, microplate reader or flow cytometer; to a high-content analysis solution found principally in screening cores at biotech and larger pharmaceutical companies. Screens for loss of viability are often the first line of inquiry, and only after an entity is shown to cause a decrease in survival is it then subjected to more nuanced assays [1]. Here we look at the principal means by which entities are tested for their effects on viability.

Disqus Comments